Last reviewed · How we verify
Rifabutin, Clarithromycin, and Clofazimine
Rifabutin, Clarithromycin, and Clofazimine is a Small molecule drug developed by Medstar Health Research Institute. It is currently FDA-approved.
Rifabutin, clarithromycin, and clofazimine are small molecule DNA inhibitors used in combination as RHB-104 to treat conditions such as Crohn's disease, Mycobacterium Avium-intracellulare infection, and multidrug-resistant tuberculosis. These medications have been studied in clinical trials for their efficacy and safety in treating various infections, including those associated with HIV and Mycobacterium Avium Ssp. Paratuberculosis.
At a glance
| Generic name | Rifabutin, Clarithromycin, and Clofazimine |
|---|---|
| Sponsor | Medstar Health Research Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (PHASE2, PHASE3)
- RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease (PHASE3)
- The Individualized M(X) Drug-resistant TB Treatment Strategy Study (PHASE4)
- Study of Four Different Treatment Approaches for Patients Who Have Mycobacterium Avium Complex Disease (MAC) Plus AIDS (PHASE3)
- A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS (PHASE2)
- Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease (PHASE3)
- Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rifabutin, Clarithromycin, and Clofazimine CI brief — competitive landscape report
- Rifabutin, Clarithromycin, and Clofazimine updates RSS · CI watch RSS
- Medstar Health Research Institute portfolio CI
Frequently asked questions about Rifabutin, Clarithromycin, and Clofazimine
What is Rifabutin, Clarithromycin, and Clofazimine?
Who makes Rifabutin, Clarithromycin, and Clofazimine?
What development phase is Rifabutin, Clarithromycin, and Clofazimine in?
Related
- Manufacturer: Medstar Health Research Institute — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing